Patents by Inventor Nancy Thornberry

Nancy Thornberry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110123443
    Abstract: A biomarker for pancreatic beta-cell mass comprising measuring the levels of CFC1 in the serum of a subject is described. The biomarker provides a noninvasive means for measuring pancreatic beta cell mass that is particularly useful for monitoring the efficacy of treatments for metabolic disorders such as Type I or Type II diabetes, including pancreatic islet cell transplantations.
    Type: Application
    Filed: April 10, 2009
    Publication date: May 26, 2011
    Applicant: MERCK & CO., INC.
    Inventors: Yun-Ping Zhou, Andrew Howard, Nancy Thornberry
  • Patent number: 7879859
    Abstract: The present application features the use of the somatostatin subtype 3 receptor (SST3) as a target for affecting insulin secretion and for diagnosing diabetes related disorders. Glucose stimulated insulin secretion was found to be stimulated by knocking down expression of SST3 and through the use of a SST3 selective antagonist.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: February 1, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yun-Ping Zhou, Jing Li, Weizhen Wu, Jin Shang, John R. Thompson, Nancy A. Thornberry
  • Publication number: 20090306037
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a particular dipeptidyl peptidase-IV (DPP-IV) inhibitor and a particular cannabinoid CB?1#191 receptor antagonist/inverse agonist, kits containing such combinations and methods of using such compositions for the treatment of diabetes, diabetes associated with obesity, diabetes-related disorders, obesity, and obesity-related disorders.
    Type: Application
    Filed: April 28, 2006
    Publication date: December 10, 2009
    Applicant: MERCK & CO., INC.
    Inventors: John M. Amatruda, Tung M. Fong, David E. Moller, Nancy A. Thornberry
  • Publication number: 20090131451
    Abstract: The present application features the use of the somatostatin subtype 3 receptor (SST3) as a target for affecting insulin secretion and for diagnosing diabetes related disorders. Glucose stimulated insulin secretion was found to be stimulated by knocking down expression of SST3 and through the use of a SST3 selective antagonist.
    Type: Application
    Filed: November 17, 2006
    Publication date: May 21, 2009
    Inventors: Yun-Ping Zhou, Jing Li, Weizhen Wu, Jin Shang, John R. Thompson, Nancy A. Thornberry
  • Publication number: 20060270722
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a particular dipeptidyl peptidase-IV (DPP-IV) inhibitor and a particular PPAR-?/? dual agonist, kits containing such combinations and methods of using such compositions for the treatment of diabetes, diabetes associated with obesity, diabetes-related disorders, obesity, and obesity-related disorders.
    Type: Application
    Filed: May 24, 2006
    Publication date: November 30, 2006
    Inventors: Nancy Thornberry, Keith Kaufman
  • Publication number: 20050112137
    Abstract: The present invention provides a method of producing autoantigens, compositions comprising autoantigenic fragments and methods of using autoantigenic fragments in the treatment of a condition associated with an autoimmune response. Also provided are assays for the detection or assessment of an autoimmune response.
    Type: Application
    Filed: October 29, 2004
    Publication date: May 26, 2005
    Inventors: Antony Rosen, Donald Nicholson, Livia Casciola-Rosen, Felipe Andrade, Sophie Roy, Nancy Thornberry
  • Patent number: 6855515
    Abstract: The present invention provides a method of producing autoantigens, compositions comprising autoantigenic fragments and methods of using autoantigenic fragments in the treatment of a condition associated with an autoimmune response. Also provided are assays for the detection or assessment of an autoimmune response.
    Type: Grant
    Filed: April 22, 1999
    Date of Patent: February 15, 2005
    Assignees: Merck & Co., Inc., Johns Hopkins University
    Inventors: Anthony Rosen, Livia Casciola-Rosen, Donald W. Nicholson, Felipe A. Andrade, Sophie Roy, Nancy A. Thornberry
  • Patent number: 6348570
    Abstract: Disclosed are novel chromophore containing compounds of Formula I and their use in determining interleukin-1&bgr; convertase (ICE) activity. ICE has been implicated in inflammatory or immune-based diseases of the lung and airways; central nervous system and surrounding membranes; the eyes and ears; joints, bones, and connective tissues; cardiovascular system including the pericardium; the gastrointestinal and urogenital systems; the skin and mucosal membranes.
    Type: Grant
    Filed: December 17, 1991
    Date of Patent: February 19, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Kevin T. Chapman, Malcolm Maccoss, Richard A. Mumford, Nancy A. Thornberry, Jeffrey R. Weidner, William K. Hagmann
  • Patent number: 5834228
    Abstract: The apopain:Ac-DEVD-CHO complex has been crystallized and its structure determined by x-ray crystallography. Based upon this crystal structure of the complex, a method for identifying inhibitors of apopain is presented which comprises designing putative inhibitors having specific contacts with apopain, making the putative inhibitors, and testing the putative inhibitors for their ability to inhibit apopain.
    Type: Grant
    Filed: February 13, 1997
    Date of Patent: November 10, 1998
    Assignees: Merck & Co., Inc., Merck Frosst Canada, Inc.
    Inventors: Joseph W. Becker, Donald W. Nicholson, Jennifer Rotonda, Nancy A. Thornberry, Kimberly M. Fazil, Michel Gallant, Yves Gareau, Marc Labelle, Erin P. Peterson, Dita M. Rasper, Rejean Ruel, John P. Vaillancourt
  • Patent number: 5434248
    Abstract: Novel peptidyl derivatives of formula I are found to be potent inhibitors of interleukin-1.beta. converting enzyme (ICE). Compounds of formula I may be useful in the treatment of inflammatory or immune-based diseases of the lung and airways; central nervous system and surrounding membranes; the eyes and ears; joints, bones, and connective tissues; cardiovascular system including the pericardium; the gastrointestinal and urogenital systems; the skin and mucosal membranes. Compounds of formula I are also useful in treating the complications of infection (e.g., gram negative shock) and tumors in which IL 1 functions as an autocrine growth factor or as a mediator of cachexia.
    Type: Grant
    Filed: June 2, 1993
    Date of Patent: July 18, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Kevin T. Chapman, Herb G. Bull, Malcolm MacCoss, Nancy A. Thornberry, Jeffrey R. Weidner, Adnan M. Mjalli